individualized treatment of early breast...

59
INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCER Ph.D. Thesis Gyöngyi Kelemen, M.D. Supervisor: Prof. Zsuzsanna Kahán, M.D., Ph.D. Department of Oncotherapy Faculty of Medicine, University of Szeged Szeged, Hungary Szeged 2012

Upload: others

Post on 24-Feb-2021

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

INDIVIDUALIZED TREATMENT OF EARLY BREAST

CANCER

Ph.D. Thesis

Gyöngyi Kelemen, M.D.

Supervisor:

Prof. Zsuzsanna Kahán, M.D., Ph.D.

Department of Oncotherapy

Faculty of Medicine, University of Szeged

Szeged, Hungary

Szeged

2012

Page 2: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

1

List of full papers that served as the basis of the Ph.D. thesis

I. Pálka I, Kelemen G, Ormándi K, Lázár G, Nyári T, Thurzó L, Kahán Z

Tumour characteristics in screen-detected and symptomatic breast cancers

Pathology & Oncology Research 14:(2) pp. 161-167. (2008)

IF: 1.260

II. Kelemen G, Farkas V, Debrah J, Ormándi K, Vörös A, Kaizer L, Varga Z, Lázár G,

Kahán Z.

The relation of multifocality and tumour burden with various tumour

characteristics and survival in early breast cancer

Neoplasma – submitted for publication

III. Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z

Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-

paclitaxel-cyclophosphamide chemotherapy in high-risk breast cancer

Oncology 78:(3-4) pp. 271-273. (2010)

IF: 2.538

IV. Kelemen Gy, Varga Z, Lázár Gy, Thurzó L, Kahán Z

Cosmetic outcome 1-5 years after breast conservative surgery, irradiation and

systemic therapy

Pathology & Oncology Research – accepted for publication

IF: 1.483

Related articles

I. Varga Z, Cserhati A, Kelemen G, Boda K, Thurzo L, Kahan Z

The role of systemic therapy in the development of lung sequelae after conformal

radiotherapy in breast cancer patients

International Journal of Radiation Oncology Physics 80:(4) pp. 1109-1116. (2011)

IF: 4.503

Page 3: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

2

II. Cserni G, Francz M, Kalman E, Kelemen G, Komjathy DC, Kovacs I, Kulka J,

Sarkadi L, Udvarhelyi N, Vass L, Voros A

Estrogen receptor negative and progesterone receptor positive breast carcinomas-

How frequent are they?

Pathology & Oncology Research 17(3):663-8. (2011)

IF:1.483

III. Dobi A, Kelemen G, Kaizer L, Weiczner R, Thurzo L, Kahan Z

Breast cancer under 40 years of age: Increasing number and worse prognosis

Pathology & Oncology Research 17:(2) pp. 425-428. (2011)

IF: 1.483

Page 4: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

3

Table of contents

LIST OF ABBREVIATIONS .................................................................................................. 4

1. INTRODUCTION ............................................................................................................. 5

2. AIMS .................................................................................................................................. 6

3. PATIENTS AND METHODS .......................................................................................... 6

3.1 TUMOUR CHARACTERISTICS IN SCREEN-DETECTED AND SYMPTOMATIC BREAST CANCERS. . 6

3.2 THE RELATION OF MULTIFOCALITY AND TUMOUR BURDEN WITH VARIOUS TUMOUR

CHARACTERISTICS AND SURVIVAL IN EARLY BREAST CANCER ....................................................... .7

3.3 THE EFFECT OF THE MAMMOGRAPHIC APPEARANCE ON SURVIVAL IN PATIENTS WITH HIGH

RISK BREAST CANCER…………………………………………………………………………..9

3.4 COSMETIC OUTCOME 1-5 YEARS AFTER BREAST CONSERVATIVE SURGERY, IRRADIATION AND

SYSTEMIC THERAPY. ................................................................................................................. 10

4. RESULTS ......................................................................................................................... 12

4.1 TUMOUR CHARACTERISTICS IN SCREEN-DETECTED AND SYMPTOMATIC BREAST CANCERS 12

4.2 THE RELATION OF MULTIFOCALITY AND TUMOUR BURDEN WITH VARIOUS TUMOUR

CHARACTERISTICS AND SURVIVAL IN EARLY BREAST CANCER ...................................................... 16

4.3 THE EFFECT OF THE MAMMOGRAPHIC APPEARANCE ON SURVIVAL IN PATIENTS WITH HIGH

RISK BREAST CANCER ............................................................................................................... 29

4.4 COSMETIC OUTCOME 1-5 YEARS AFTER BREAST CONSERVATIVE SURGERY, IRRADIATION AND

SYSTEMIC THERAPY .................................................................................................................. 31

5. DISCUSSION .................................................................................................................. 41

6. SUMMARY, CONCLUSIONS ...................................................................................... 48

7. ACKNOWLEDGEMENTS ............................................................................................ 49

8. REFERENCES ................................................................................................................ 50

9. APPENDIX ...................................................................................................................... 58

Page 5: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

4

List of abbreviations

ABD axillary lymph node dissection

ATC adriamycin (A)-paclitaxel (T)-cyclophosphamide (C)

BCSS breast cancer-specific survival

BS breast separation

CMF cyclophosphamide, methotrexate and fluorouracil

DCIS ductal carcinoma in situ

DDFS distant disease-free survival

ER oestrogen receptor

FISH fluorescence in situ hybridization

HER2 human epidermal growth factor receptor 2

IMRT intensity-modulated radiation therapy

LVI lymphovascular invasion

OAR organ at risk

OS overall survival

pT size of the largest invasive tumour focus

PTV planning target volume

PR progesterone receptor

RFS relapse-free survival

SNB sentinel lymph node biopsy

TOP2A topoisomerase2-alpha

Page 6: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

5

1. Introduction

Breast carcinoma is a diverse disease entity, and the therapy should be based on specific

markers reflecting its individual biological behaviour [1-3]. The currently used prognostic

factors, however, do not reliably distinguish between true early breast cancers (usually screen-

detected and small, with a cure rate of around 95%), and those that exhibit an apparently low

TNM status, but in fact are at a more advanced stage with a high risk of relapse [3-6]. The

role of mammographic service screening in the reduction of breast cancer mortality has been

consistently revealed in numerous randomized controlled clinical studies and meta-analyses

[7-11]. Thus, breast cancer-related mortality is significantly reduced in women invited to

mammographic service screening as compared with those not invited to participate [7-11].

The type of mammographic image has recently been suggested as an independent prognostic

factor. The presence of casting-type calcifications has been demonstrated to be a prognostic

factor which carries a significantly higher risk of death as compared with cancers not

associated with this mammographic abnormality [2, 12-16]. In contrast, stellate lesions on the

mammogram reflect a more favourable prognosis than any other mammographic appearances

[2, 16-17]. The prognostic significance of multifocality/multicentricity and the tumour burden

have long been the subjects of investigation, but the results are inconclusive as the

nomenclature and methods applied were not uniform [1,18-23]. A larger tumour burden due

to multifocality has been related to poorer pathological characteristics [1, 18, 19], relapse-free

survival (RFS) [18, 23] and overall survival (OS) [18, 21, 22, 24]. In the case of multifocal

breast cancers, therefore, a consideration of the TNM stage alone, would lead to inaccurate

conclusions during treatment decision-making.

Breast-conserving surgery, usually followed by whole-breast irradiation, is the most

widely used surgical option for early breast cancer [25-29]. The cosmetic and the functional

outcome after postoperative breast radiotherapy depend on numerous patient- and therapy-

related factors. The radiogenic changes of the breast, such as dyspigmentation, teleangiectasia

or breast oedema, fibrosis causing breast swelling and tenderness, depend on the dose, the

irradiated volume and the individual radiosensitivity [30-33]. The impact of the systemic

therapy on the cosmetic outcome has been the subject of numerous studies [34-38].

Page 7: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

6

2. Aims

2.1 We set out to prospectively investigate the patient- and tumour-related features in

early breast cancer shortly after the introduction of mammographic service-screening in

Hungary.

2.2 In an extended database, we aimed at the evaluation of how the multifocality and

calculated tumour burden in operable breast carcinomas relate to conventional pathological

and other tumour features, and the assessment of their effects on the outcome.

2.3 The aim of a retrospective analysis of a clinical study with adjuvant dose-dense

sequential adriamycin-paclitaxel-cyclophosphamide (ATC) chemotherapy was to investigate the

impact of the breast cancers’ mammographic appearance on survival in high risk breast cancer

cases.

2.4 In a retrospective cohort analysis, we intended to study the patient- and therapy related

factors that may influence the cosmetic and functional outcomes among our breast cancer

patients after breast-conserving surgery and conformal radiotherapy, with or without adjuvant

systemic therapy.

3. Patients and methods

3.1 Tumour characteristics in screen-detected and symptomatic breast cancers

Patients attending the Breast Unit of the University of Szeged, Hungary between May

1, 2004 and January 1, 2007 were eligible to take part in this study.

Page 8: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

7

The following data were prospectively registered: the age of the patient at the time of

breast surgery, the type of breast surgery (breast-conserving surgery vs mastectomy), the

type of lymph node surgery (sentinel lymph node biopsy (SNB) vs axillary lymph node

dissection (ABD)), the pathological size of the largest invasive focus (pT), the histological

type, the histological grade, the hormone receptor (oestrogen receptor (ER) and progesterone

receptor (PR)) and human epidermal growth factor receptor 2 (HER2) status of the tumour

and the presence of lymphovascular invasion (LVI). The mode of detection of the

breast cancer was registered in the following categories: screen-detected (detected by breast

imaging within the national mammography screening program or by opportunistic

screening), symptomatic (detected via any symptom related to the tumour in a patient who did

not attend any screening program in the last two years) or interval cancer (the tumour was

diagnosed during the interval between two successive screening rounds and within 2

years after a negative screening finding). The mammographic appearance of the tumour,

based on the mammography report, was registered. Mammographic images were classified

according to Tabár et al. [12]. For the analysis of the association between the mammographic

image and other characteristics of the tumour, the previous categories were grouped in the

following way: spiculated lesions without calcifications, casting-type calcifications with or

without an associated tumour mass, and others.

Statistical analysis

For the categorical parameters, chi-square or Fisher tests were applied; for the analysis of

continuous data, variance analysis was used.

3.2 The relation of multifocality and tumour burden with various tumour characteristics

and survival in early breast cancer

Women attending the Breast Unit at the University of Szeged with invasive breast cancer in

clinical stage I or II between May 2004 and August 2010 were eligible for this study. All

patients underwent primary breast surgery, and adjuvant therapy was administered in

accordance with the national and international guidelines.

The data recorded were the age of the patient at the time of breast surgery, the mode of

detection of the breast cancer (mammography screening-detected, detected other than by

mammography screening or interval cancer) and its mammographic appearance. The

Page 9: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

8

radiologic images were categorized as stellate (spiculated) tumour masses, circular tumours,

and parenchymal dystorsion/asymmetric density, while malignant microcalcifications were

categorized into two groups: casting-type calcifications and non-casting-type calcifications.

For the analysis of the association between the mammographic image and survival, these

categories were grouped as: stellate lesions without casting-type calcifications, casting-type

calcifications with or without an associated tumour mass and others. The type of breast

surgery (breast-conserving surgery vs. mastectomy), the type of lymph node surgery (SNB

vs. ABD with or without SNB), the pT, the histological type, the histological grade, the

presence of LVI and the information on lymph node involvement were also compiled. The

percentages of cells expressing the ER, the PR, Ki67 and topoisomerase2-alpha (TOP2A)

protein were routinely determined by means of immunohistochemistry [39]. A cut-off value

of ≥10% was used for ER or PR positivity, and >15% for TOP2A or Ki67 positivity. The

HER2 status was determined via immunohistochemistry and/or HER2 fluorescence in situ

hybridization (FISH) [39]. Immunohistochemistry data were not available for all patients.

Additionally, we retrospectively extracted the following data from the pathological reports:

the presence of multifocality, the sizes of the multiple foci (both invasive and in situ foci, if

present), and the grade of the in situ component, if present. Pathological reports were

considered only if there was a clear allusion to the presence or absence of more than one

tumour focus. In all cases, large-format histological sections (maximum size 60x90 mm) were

examined. The criterion of multifocality was the presence of more than one cancer focus

separated by non-malignant breast tissue. If two or more invasive foci were present, the

tumour was classified as invasive multifocal. Since most of the pathological reports did not

provide the extent of the breast parenchyma involved by malignant structures, the

pathological extent of the disease was estimated by summing the largest diameters of the

invasive and in situ cancer foci; this measure was taken as the tumour burden. In unifocal

cases, the tumour size comprised the tumour burden. Analyses were made on the basis of the

presence of multifocality, the magnitude of the tumour burden, other pathological features and

the survival data.

Survival data were collected on the basis of regular 6-month follow-up visits or events such as

relapse or death. RFS was defined as the time from breast surgery to any instance of disease

recurrence (local, regional or distant relapse or a contralateral breast cancer). Breast cancer-

Page 10: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

9

specific survival (BCSS) was defined as the time from breast surgery to death due to breast

cancer. For the survival analyses, we excluded patients operated on after 2007. RFS and

BCSS were studied in relation to the patient and tumour characteristics; the median value (19

mm) of the tumour burden was applied as a cut-off value. In order to detect a difference in

outcome between the apparently early (cancers <15 mm) and more advanced cases as a

function of the studied variables, survival analysis was performed separately on a subgroup of

patients with breast cancers measuring <15 mm, regardless of whether they were unifocal or

multifocal.

Statistical analyses

For the categorical parameters, the chi-square test was applied; for the analysis of continuous

data, variance analysis and the Kruskal-Wallis test were used. The effects of the different

patient and pathological characteristics on the disease outcome were assessed with the

Kaplan-Meier method, and the effects of the various tumour-related factors on the disease

outcome were evaluated with the Cox proportional hazards model. Statistical analysis was

performed with SPSS 15.0 for Windows.

3.3 The effect of the mammographic appearance on survival in patients with high risk

breast cancer

Data of patients with high-risk breast cancer who received 4 cycles of adriamycin 60 mg/m2,

paclitaxel 200 mg/m2 and cyclophosphamide 800 mg/m

2 respectively, every 2 weeks were

prospectively collected.

RFS and OS were defined as the time from enrolment to any disease recurrence (local,

regional, distant relapse or contralateral breast cancer) or to death. After chemotherapy,

during the first 5 years of follow-up, patients had regular checkups every 6 months including

chest X-ray, abdominal ultrasound, blood tests, bilateral mammography and bone scan.

Statistical analyses

Kaplan-Meier survival analysis and the Breslow test were used.

Page 11: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

10

3.4 Cosmetic outcome 1-5 years after breast conservative surgery, irradiation and systemic

therapy

Eligible patients had undergone unilateral breast-conserving surgery, with or without SNB

or/and ABD and conformal radiotherapy 1-5 years before the interview. Patients with prior

malignancy or any other significant health problem were excluded, as were those on

glucocorticoid therapy. The patients had been operated between May 2004 and December

2008, at either the Department of Surgery, University of Szeged, or at smaller surgical

departments.

Use of the following adjuvant medical therapies was permitted: a taxane-based postoperative

chemotherapy regimen (involving either docetaxel or paclitaxel at conventional doses)

completed 4 weeks prior to the radiotherapy (n=23, 13.1%); adjuvant hormone therapy with

either tamoxifen (20 mg/day) or an aromatase inhibitor (anastrozole, 1 mg/day, or letrozole,

2.5 mg/day), started 2 weeks before the initiation of radiotherapy (n=49, 24.7% and n=48,

24.2%, respectively); patients who did not receive any systemic medication during or after the

radiotherapy were also eligible for enrolment (n=75, 37.9%).

CT-based three-dimensional treatment planning and conformal radiotherapy were performed

in all cases with the patient in a supine position. All relevant technical details have been

published previously [40]. Briefly, CT images were acquired at 1 cm intervals throughout the

entire planning volume. The target volume and organs at risk (OARs) were contoured on the

CT slices in the radiotherapy planning system. The planning target volume (PTV) coverage

was analyzed via the dose-volume histograms and isodose visualization. Local or locoregional

radiotherapy was chosen according to the local protocol. The tumour bed boost was delivered

with either 6 MV photon or 8-15 MeV electron fields. The radiation dose to the remaining

breast parenchyma/chest wall and to the lymph nodes, if indicated, was 25x2 Gy (prescribed

to the mean of the PTV); a tumour bed boost of 5-8x2 Gy was delivered when necessary.

OAR constraints were used as previously described [40].

The following radiotherapy-related data were extracted from our database: the PTV, the

volume of the PTV that received more than 47.5 Gy, but less than 53.5 Gy (V95%–107%),

the overdosed volume of the PTV (V>107%), the volume and dose of the tumour bed boost,

Page 12: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

11

the technique used and the breast separation (BS), i.e. the distance between the points at

which the tangential fields entered the body.

The cosmetic outcome was evaluated at a single routine 6-month check-up visit, 1-5 years

after the radiotherapy. The patients were examined, and a questionnaire relating to the

following items was completed: the overall cosmetic success in the opinions of the patient and

the physician (G. K. or Z. K.), the presence of breast fibrosis or oedema, teleangiectasia or

dyspigmentation, all scored on a 4-point categorical scale according to the modified system of

Johansen et al. [36, 41]. Briefly, the following scoring system was used. Breast fibrosis: 0:

none, 1: density slightly increased, 2: increased density and firmness, 3: very marked density

with retraction; Oedema: 0: none, 1: trace thickening of the skin, 2: marked oedema, leathery

skin texture, 3: severe oedema with papillary formation; Teleangiectasia: 0: none, 1: < 1 cm,

2: 1-4 cm, 3: >4 cm; Dyspigmentation: 0: none, 1: mild, 2: moderate, 3: severe. Physicians

classified the cosmetic result as excellent if no asymmetry or changes of the skin or the breast

contour occurred; in the case of slight, moderate or severe manifestation of at least one of

these factors, the outcome was considered good, fair or poor, respectively. The patients were

asked whether they felt pain or tenderness in the operated breast, and whether they had

experienced changes in their body image or in their clothing habits. The length of the excision

scar and the difference (regarded as measurable when ≥1.0 cm) in the jugulum-nipple distance

(indicative of breast asymmetry) were recorded. Data were additionally collected on smoking

habits, with the participants categorized as past or present smokers or non-smokers.

Statistical analyses

The various patient- and radiotherapy-related characteristics associated with the cosmetic and

functional outcomes were analyzed by the means of the chi-square test, analysis of variance

and logistic regression. The Kappa test was applied to investigate the connection between the

opinions of the physicians and the patients as concerns the cosmetic outcome. Binary

univariate logistic regression models were first utilized separately, followed by the

multivariate logistic regression model to examine joint effects and interactions. Statistical

analysis was performed with SPSS 15.0 for Windows.

Page 13: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

12

4. Results

4.1 Tumour characteristics in screen-detected and symptomatic breast cancers

The data on 565 patients with 569 invasive breast cancers were collected. (Four patients had

synchronous bilateral invasive breast cancer.)

Patient- and tumour-related characteristics according to the mode of detection

Overall, 258 tumours (46%) were screen-detected, while 263 (46%) were symptomatic and

48 (8%) were interval cancers. The mean±SD age of the overall patient population at the

time of breast surgery was 58.1±10.9 years (range 27.8–85.1), while that of the cases with

screen-detected or symptomatic tumours was 58.4±7.6 and 58.5±13.9 years, respectively, and

that of the patients with interval cancers was 54.3±5.4 years (p=0.04). While 35.4% of the

patients with interval cancer, and 31% of the patients with symptomatic cancer were

premenopausal, only 20.2% of the patients with screen-detected cancer were

premenopausal (p=0.007). The pathological tumour characteristics are presented in Table 1.

Surgical and medical treatment options according to the mode of detection

The rate of breast-conserving surgery among the patients with screen-detected cancers was

significantly (p<0.001) higher than that in symptomatic or interval cancer cases.

Similarly, the rate of SNB was the highest in the group with screen-detected tumours

(p<0.001). In 15 clinically node-negative cases, no axillary surgery was performed because of

the advanced age of the patient. Adjuvant chemotherapy was significantly less frequently

applied in the patients with screen-detected cancers (36.8%) than in the symptomatic

(53.6%) or interval cancer (66.7%) cases (p<0.001). The frequency of use of hormone therapy

was similar in the three groups (Table 2).

Patient- and tumour-related characteristics according to the mammographic image

In two cases, no mammography had been performed prior to surgery, and in another three

cases, the result of the mammography was not available. Different characteristics according

to the mammographic image are presented in table 3. The cancers associated with casting-

type calcifications on the mammogram were significantly more often of ductal type (p=0.043,

Fisher’s exact test), of grade 3 (p<0.001), ER- and PR-negative (p<0.001) and HER2-positive

(p<0.001) than the cancers without casting calcifications. The mammographic images

revealed no differences in tumour size, lymph node status or LVI.

Page 14: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

13

Screen-detected

(%)

Symptomatic (%) Interval cancer

(%)

p

Histological type

Invasive ductal

carcinoma

201/258 (78.2) 203/263 (77.2) 31/48 (64.6) 0.168 (chi-square test)

Invasive lobular

carcinoma

35/258 (13.6) 38/263 (14.4) 7/48 (14.6) 0.21 (Fisher’s exact test)

Others

(medullary,

mucinous,

tubular,

papillary)

22/258 (8.2) 22/263 (8.4) 10/48 (20.8)

Grade

1 75/257 (29.2) 26/260 (10.0) 8/48 (16.7) <0.001 (chi-square test)

2 115/257 (44.7) 124/260 (47.7) 22/48 (45.8)

3 67/257 (26.1) 110/260 (42.3) 18/48 (37.5)

Tumour size

1–10 mm 88/258 (34.1) 19/263 (7.2) 3/48 (6.2) <0.001 (chi-square test)

11–20 mm 120/258 (46.5) 93/263 (35.4) 24/48 (50)

>20 mm 50/258 (19.4) 151/263 (57.4) 21/48 (43.8)

Node

Negative 179/258 (69.4) 127/263 (48.3) 24/48 (50) <0.001 (chi-square test)

Positive 79/258 (30.6) 136/263 (51.7) 24/48 (50)

LVI

Negative 217/258 (84.1) 186/263 (70.7) 37/48 (77.1) 0.001 (chi-square test)

Positive 41/258 (15.9) 77/263 (29.3) 11/48 (22.9)

ER and PR

Positive 218/257 (84.8) 208/262 (79.4) 37/48 (77.1) 0.193 (chi square test)

Negative 39/257 (15.2) 54/262 (20.6) 11/48 (22.9)

HER2

Negative 222/255 (87.1) 220/262 (84.0) 38/48 (79.2) 0.310 (chi-square test)

Positive 33/255 (12.9) 42/262 (16.0) 10/48 (20.8)

Table 1 Pathological tumour characteristics for the various modes of detection

Page 15: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

14

Screen-

detected n=258 (%)

Symptomatic n=263 (%)

Interval cancer n=48 (%)

p (chi-square

test)

Breast surgery

Breast-conserving

surgery

223 (86.4) 131 (49.8) 26 (54.2) <0.001

Mastectomy 35 (13.6) 132 (50.2) 22 (45.8)

Lymph node surgery

Sentinel node

biopsy

116 (45.0) 43 (16.3) 10 (20.8) <0.001

Axillary lymph node

dissection±sentinel

biopsy

137 (53.1) 210 (79.8) 38 (79.2)

No axillary

surgery

5 (1.9) 10 (3.9) 0 (0)

Adjuvant

chemotherapy

No 163 (63.2) 122 (46.4) 16 (33.3) <0.001

Yes 95 (36.8) 141 (53.6) 32 (66.7)

Adjuvant hormone

therapy

No 93 (36.1) 80 (30.4) 16 (33.3) 0.395

Yes 165 (63.9) 183 (69.6) 32 (66.7)

Table 2 Surgical and medical therapy following the various modes of detection of breast

cancer

Page 16: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

15

Stellate lesions

without

calcifications (%)

Casting-type

calcifications ±

associated

tumour mass

(%)

Others (%) p

Histological

type

Invasive

ductal cancer

165/213 (77.5) 38/40 (95) 229/311 (73.5) 0.056 (chi-square test)

Invasive

lobular cancer

29/213 (13.6) 1/40 (2.5) 48/311 (15.4) 0.046 (Fisher’s exact

test)

Others

(medullary,

mucinous,

tubular,

papillary)

19/213 (8.9) 1/40 (2.5) 34/311 (10.1)

Grade

1 55/212 (25.9) 2/40 (5.0) 52/308 (16.9) <0.001 (chi-square test)

2 110/212 (51.9) 11/40 (27.5) 136/308 (44.2)

3 47/212 (22.2) 27/40 (67.5) 120/308 (38.9)

Tumour size

1-10 mm 42/213 (19.7) 8/40 (20.0) 59/311 (19.0) 0.098 (chi-square test)

11-20 mm 100/213 (47.0) 11/40 (27.5) 123/311 (39.5)

>20 mm 71/213 (33.3) 21/40 (52.5) 129/311 (41.5)

Node

Negative 123/213 (57.7) 19/40 (47.5) 185/311 (59.5) 0.350 (chi-square test)

Positive 90/213 (42.3) 21/40 (52.5) 126/311 (40.5)

LVI

Negative 168/213 (78.9) 27/40 (67.5) 241/311 (77.5) 0.287 (chi-square test)

Positive 45/213 (21.1) 13/40 (32.5) 70/311 (22.5)

ER and PR

Positive 189/212 (89.1) 23/40 (42.5) 247/310 (79.7) <0.001 (chi-square test)

Negative 23/212 (10.9) 17/40 (57.5) 63/310 (20.3)

HER2

Negative 198/212 (93.4) 18/40 (45.0) 259/308 (84.1) <0.001 (chi-square test)

Positive 14/212 (6.6) 22/40 (55.0) 49/308 (15.9)

Table 3 Comparison of the pathological tumour characteristics with the mammographic

image

Page 17: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

16

4.2 The relation of multifocality and tumour burden with various tumour characteristics

and survival in early breast cancer

Among a total of 1234 breast carcinoma cases, 1071 were eligible for the analysis. The

mean±SD age was 58.6±12.0 (range 24.5-88.6) years. The patient and tumour characteristics

are presented in Tables 4 and 5. Around 40% of the cases were screen-detected. Among the

796 (74.3%) unifocal and 275 (25.7%) multifocal cancers found, there were 101 multifocal

invasive tumours, while in 174 cases a single invasive focus was associated with one or more

in situ foci.

The connection of multifocality with different tumour features

Multifocal cancers were more susceptible to screen detection, HER2 positivity and casting

calcifications in the mammogram than were unifocal cancers. Invasive multifocality was more

strongly associated than non-invasive multifocality with mastectomy (44% vs. 28%, p<0.01),

lymph node positivity (47 vs. 35%, p=0.03) and HER2 positivity (17 vs. 9%, p=0.02). The

maximum diameter of unifocal cancers was greater than the largest tumour focus in multifocal

cancers (p<0.001).

The connection between the tumour burden and different patient and tumour characteristics

The calculated mean±SE tumour burden in the unifocal and the multifocal cases was 19.5±0.4

and 31.2±0.9, respectively (p<0.001). We analyzed the standard pathological parameters

according to the tumour burden, using the median value of 19.0 mm as a threshold (Table 6).

The presence of lymph node metastases (p<0.001) or LVI (p<0.001) was associated with a

larger tumour burden. The mean±SE tumour burden was 21.7±0.4 vs. 28.9±1.4 mm in

invasive ductal vs. lobular carcinomas, respectively (p<0.01). A larger invasive tumour focus

and a larger tumour burden predisposed to ER, PR negativity (p<0.001) and HER2 positivity

(p<0.001). In multivariate analysis, only the connections between the tumour burden and ER,

PR negativity and HER2 positivity remained significant (p<0.001). A larger tumour burden

was associated with Ki67 positivity (p=0.02). A tumour burden larger than the cut-off value

was related to multifocality (p<0.001). The mean±SE tumour burden was 32.6±0.2 mm in

cases where there were casting calcifications in the mammogram, and 20.9±0.6 mm when the

lesion was categorized as a spiculated mass (p<0.001).

Page 18: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

17

Variable Unifocal

cancers

(n=796)

(%)

Multifocal

cancers

(n=275)

(%)

p All

(n=1071)

(%)

Age (mean±SD) 58.7±12.2 58.5±11.5 0.87 58.6±12.0

Mode of

detection

Screen-detected

Symptomatic+interval

312 (39.2)

484 (60.8)

130 (47.3)

145 (52.7)

0.02 442 (41.3)

629 (58.7)

Mammographic

appearance

Stellate

Casting-type

Calcification±tumour mass

Other

308 (39.1)

35 (4.4)

444 (56.4)

78 (28.4)

51 (18.5)

146(53.1)

<0.001 386 (36.3)

86 (8.1)

590 (55.6)

Breast surgery

Excision

Mastectomy

570 (71.6)

226 (28.4)

186 (67.6)

89 (32.4)

0.22 756 (70.6)

315 (29.4)

Lymph node

surgery

Sentinel lymph node biopsy

or nothing

Axillary lymph node

dissection±sentinel lymph

node biopsy

382 (48.0)

414 (52.0)

139 (50.5)

136 (49.5)

0.48 382 (48.6)

414 (51.4)

Table 4 Patient-, tumour- and surgery-related parameters in unifocal and multifocal cancers

Page 19: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

18

Variable Unifocal

cancers

(n=796) (%)

Multifocal

cancers

(n=275) (%)

p

(multifocal

versus

unifocal)

All

(n=1071)

(%)

Invasive

multifocal

cancers

(n=101) (%)

p

(invasive

multifocal

versus

unifocal)

All

(n=897)

(%)

Tumour size

(mean±SD) 19.5±10.8 16.3±9.6 <0.001 18.6±10.6 18.1±10.1 0.24 19.3±10.7

Lymph node

status

negative

positive

510 (64.1)

286 (35.9)

173 (62.9)

102 (37.1)

0.77 683 (63.8)

388 (36.2)

54 (53.5)

47 (46.5)

<0.05 564 (62.9)

333 (37.1)

Histological

type of the

invasive

component

Invasive ductal

carcinoma

Invasive lobular

carcinoma

Other

620 (77.9)

93 (11.7)

83 (10.4)

220 (80.0)

32 (11.6)

23 (8.4)

0.61 840 (78.4)

125 (11.7)

106 (9.9)

77 (76.2)

18 (17.8)

6 (5.9)

0.10 697 (77.7)

111 (12.4)

89 (9.9)

Grade

1

2 or 3

113 (14.3)

676 (85.7)

45(16.5)

228 (83.5)

0.38

n=1062

158 (14.9)

904 (85.1)

16 (16.2)

83 (83.8)

0.65

n=888

129 (14.5)

759 (85.5)

Presence of

DCIS

n=295 n=197 0.49 n=492 n=58 n=353

Page 20: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

19

Grade 1

Grade 2

Grade 3

40 (13.6)

85 (28.8)

170 (57.6)

24 (12.2)

49 (24.9)

124 (62.9)

4 (13.0)

134 (27.2)

294 (59.8)

9 (15.5)

25 (43.1)

24 (41.4)

0.06 49 (13.9)

110 (31.2)

194 (55.0)

Presence of

LVI

LVI-

LVI+

648 (81.4)

148 (18.6)

224 (81.5)

51 (18.5)

1.00 872 (81.4)

199 (18.6)

88 (87.1)

13 (12.9)

0.17 736 (82.1)

161 (17.9)

ER status

ER+

ER-

606 (76.5)

186 (23.5)

198 (72.0)

77 (28.0)

0.14

n=1067

804 (75.4)

263 (24.6)

78 (77.2)

23 (22.8)

1.00

n=893

684 (76.6)

209 (23.4)

PR status

PR+

PR-

565 (70.9)

231 (29.1)

180 (65.5)

95 (34.5)

0.09

n=1069

743 (69.5)

326 (30.5)

70 (69.3)

31 (30.7)

0.73

n=895

633 (70.7)

262 (29.3)

Ki67 status

Ki67+

Ki67-

119 (40.8)

173 (59.2)

37 (52.9)

33 (47.1)

0.08

n=362

156 (43.1)

206 (56.9)

15 (51.7)

14 (48.3)

0.32

n=321

134 (41.7)

187 (58.3)

TOP2A status

TOP2A+

59 (26.6)

19 (31.1)

0.52

n=283

78 (27.6)

8 (32.0)

0.64

n=247

67 (27.1)

Page 21: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

20

Table 5 Routinely assessed pathological parameters among unifocal, multifocal and invasive multifocal

TOP2A- 163 (73.4) 42 (68.9) 205 (72.4) 17 (68.0) 180 (72.9)

HER2 status

HER2+

HER2-

58 (7.4)

723 (92.6)

46 (17.2)

221 (82.8)

<0.001

n=1048

104 (9.9)

944 (90.1)

17 (17.3)

81 (82.7)

0.003

n=879

75 (8.5)

804 (91.5)

Triple

negativity

Yes

No

106 (13.4)

683 (86.6)

26 (9.5)

248 (90.5)

0.09

n=1063

132 (12.4)

931 (87.6)

7 (6.9)

94 (93.1)

0.08

n=890

113 (12.7)

777 (87.3)

Page 22: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

21

Variable Tumour burden

≤19 mm (n=536)

Tumour burden

>19 mm (n=535) p

Tumour size

(mean±SD) 12.4±3.9 24.9±11.4 <0.001

Lymph node

status

negative

positive

383 (71.5)

153 (28.5)

300 (56.1)

235 (43.9)

<0.001

Histological

type

Invasive ductal

carcinoma

Invasive lobular

carcinoma

Other

437 (81.5)

46 (8.6)

53 (9.9)

403 (75.3)

79 (14.8)

53 (9.9)

0.01

Grade 1

2 or 3

118 (22.2)

411 (77.8)

40 (7.5)

490 (92.5)

<0.001

Presence of

DCIS

Grade 1

Grade 2

Grade 3

n= 219 (44.5% of

all)

44 (20.1)

69 (31.5)

106 (48.4)

n=273 (55.5% of

all)

20 (7.3)

65 (23.8)

188 (68.9)

<0.001

Presence of

LVI

LVI-

LVI+

460 (85.8)

76 (14.2)

412 (77.0)

123 (23.0)

<0.001

ER status

n=1067

ER+

ER-

436 (82.0)

96 (31.2)

368 (68.8)

167 (31.2)

<0.001

PR status

n=1069

PR+

PR-

403 (75.5)

131 (24.5)

340 (63.6)

195 (36.4)

<0.001

Ki67 status

n=362

Ki67+

Ki67-

76 (37.4)

127 (62.6)

80 (50.3)

79 (49.7)

0.02

Page 23: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

22

TOP2A status

n=283

TOP2A+

TOP2A-

38 (24.7)

116(75.3)

40 (31.0)

89 (69.0)

0.29

HER2 status

n=1048

HER2+

HER2-

39 (7.4)

486 (92.6)

65 (12.4)

458 (87.6)

0.01

Multifocality

n=1071

Yes

No

60 (11.2)

476 (88.8)

215 (40.2)

320 (59.8)

<0.001

Table 6 Routinely assessed pathological parameters in 1071 breast cancers according to

tumour burden

Page 24: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

23

Survival data

The median follow-up time for the population of 584 patients participating in the survival

analysis was 5.0 (range 0.3-7.3) years. There were 65 relapses (12.7%) and 30 deaths (5.8%).

The numbers of relapses and deaths in the multifocal vs. the unifocal cases were 17 vs. 48 and

7 vs. 23, respectively. The survival data did not differ as a function of the presence of

multifocality in the population. Among the conventional tumour characteristics, a larger

invasive tumour, the presence of LVI or lymph node involvement, HER2 positivity and triple

negativity were associated with a poorer RFS and OS (Table 7). The grade of the invasive

tumour was not related to the RFS. As regards the mode of detection, screen-detected tumours

gave RFS and OS statistics that were superior to those for non-screen-detected or interval

cancers. The mammographic appearance of the tumour was not related to the outcome. A

tumour burden >19 mm or >40 mm (extensive tumour) involved a shorter RFS and OS.

Neither multifocality nor invasive multifocality was associated with a shorter RFS or OS.

In Cox proportional hazards models, the pT, the lymph node status, triple negativity

and HER2 positivity remained independent determinants of an increased risk of relapse or

death (Tables 8 and 9).

Page 25: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

24

Overall population (n=584)

RFS

estimated mean (±SE, years)

OS

estimated mean (±SE, years)

Largest invasive

tumour

<15 mm 7.0±0.1 7.3±0.0

≥15 mm 6.4±0.1 6.9±0.1

p (Mantel-Cox) <0.001 <0.001

Lymph node positivity

Yes 6.1±0.2 6.8±0.1

No 7.0±0.1 7.2±0.0

p (Mantel-Cox) <0.001 <0.001

Invasive tumour

grade

1 6.9±0.2 7.3*

2 or 3 6.6±0.1 6.9±0.6

p (Mantel-Cox) =0.17 =0.03

Presence of LVI

Yes 6.2±0.2 6.7±0.1

No 6.8±0.1 7.2±0.1

p (Mantel-Cox) =0.02 =0.004

HER2

Positive 5.7±0.4 6.3±0.2

Negative 6.7±0.1 7.1±0.1

p (Mantel-Cox) <0.001 <0.001

Triple negative

Yes 6.0±0.3 6.5 ±0.2

Page 26: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

25

No 6.7±0.1 7.1±0.1

p (Mantel-Cox) =0.02 =0.002

Mode of detection

Screen-detected 6.9±0.1 7.2±0.1

Interval and non-

screen-detected cancer

6.4±0.1 6.9±0.1

p (Mantel-Cox) =0.001 =0.01

Mammographic

appearance

Spiculated tumour

mass without casting

calcification

6.7±0.1 7.1±0.1

Casting calcification ±

tumour mass

6.4±0.3 6.9±0.2

Other 6.7±0.1 7.1±0.1

p (Mantel-Cox) =0.66 =0.70

Multifocality

Yes 6.6±0.1 7.0±0.1

No 6.7±0.1 7.1±0.1

p (Mantel-Cox) =0.45 =0.59

Invasive multifocality

Yes 6.5±0.3 7.1±0.1

No 6.7±0.1 6.9±0.1

p (Mantel-Cox) =0.94 =0.70

Tumour burden

≤19 mm 6.7±0.1 7.1±0.1

>19 mm 6.5±0.1 6.9±0.1

p (Mantel-Cox) =0.09 =0.03

Tumour burden

<40 mm 6.7±0.1 7.1±0.1

Page 27: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

26

≥40 mm 5.9±0.3 6.5±0.2

p (Mantel-Cox) =0.04 =0.02

*All cases are censored

Table 7 The effects of selected variables on disease outcome (median RFS and OS) among

the cases participating in the survival analysis

Page 28: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

27

Variable Univariate

HR (95% CI)

p Multivariate

HR (95% CI) p

pT ≥15 vs. <15

mm

3.4 (1.8-6.5) <0.001 2.0 (1.0-4.0) 0.05

Lymph node-

positive vs. lymph

node-negative

3.8 (2.3-6.4) <0.001 3.0 (1.7-5.3) <0.001

Grade 2-3 vs.

grade 1 (invasive

component)

1.9 (0.8-4.7) 0.17

Presence of LVI 1.8 (1.1-2.9) 0.02 1.1 (0.6-1.7) 0.97

HER2 positivity 2.9 (1.7-5.3) <0.001 3.1 (1.7-5.8) <0.001

Triple negativity 1.8 (0.9-3.4) 0.06 2.2 (1.1-4.4) 0.02

Non-screen-

detected or

interval vs. screen-

detected

2.5 (1.4-4.3) <0.001 1.6 (0.9-2.8) 0.15

Casting

calcification vs.

spiculated tumour

mass

1.5 (0.6-3.8) 0.37

Spiculated tumour

mass vs. other

1.1 (0.7-1.9) 0.69

Presence of

multifocality

0.8 (0.5-1.4) 0.45

Tumour burden

>19 mm

1.5 (0.9-2.6) 0.09

Tumour burden

>40 mm

1.8 (1.1-3.4) 0.05 1.0 (0.5-2.0) 0.98

Table 8 The effects of selected patient- and tumour-related features on the risk of relapse

according to the Cox proportional hazards model: univariate and multivariate analysis

Page 29: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

28

Category Univariate

HR (95% CI)

p Multivariate

HR (95% CI) p

pT ≥15 vs. <15 mm 8.9 (2.1-37.7) 0.03 2.5 (1.2-5.2) 0.03

Lymph node

positivity

5.0 (2.1-11.9) <0.001 3.3 (1.4-8.2) 0.01

Grade 2-3 vs. grade

1 (invasive

component)

25.2 (0.2-3012.88) 0.18

Presence of LVI 2.9 (1.3-6.1) 0.01 1.3 (0.6-3.0) 0.48

HER2 positivity 5.8 (2.6-12.7) <0.001 8.4 (3.2-22.1) <0.001

Triple negativity 3.5 (1.5-8.1) 0.003 6.8 (2.5-18.5) <0.001

Non-screen-detected

or interval vs.

screen-detected

3.7 (1.4-9.6) 0.01 2.3 (0.8-6.9) 0.13

Casting calcification

vs. spiculated

tumour mass

1.7 (0.5-6.4) 0.42

Spiculated tumour

mass vs. other

1.3 (0.5-3.0) 0.59

Presence of

multifocality

0.8 (0.3-1.9) 0.59

Tumour burden >19

mm

2.6 (1.1.-6.1) 0.03 0.8 (0.3-2.1) 0.65

Tumour burden >40

mm

2.6 (1.1-6.2) 0.03 0.9 (0.3-2.7) 0.94

Table 9 The effects of selected patient- and tumour-related features on the risk of death due to

breast cancer according to the Cox proportional hazards model: univariate and multivariate

analysis

Page 30: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

29

4.3 The effect of the mammographic appearance on survival in patients with high risk

breast cancer

After a median follow-up time of 78.5 (64.3–100.0) months, 29 patients (52.7%) were free of

relapse, 34 patients (61.8%) were free of distant metastases, and 36 (65.5%) patients survived.

The median times of RFS, distant disease-free survival (DDFS) and OS were not yet reached

at 100.0 months. Two patients developed local relapse, 3 contralateral breast cancers and 21

distant metastases as follows: 3 lung, 3 bone, 2 liver, 1 brain and 1 pleural relapse; in 7, 3 and

1 cases metastases affected 2, 3 and 4 organs at the same time. Two other patients developed

second primary mesopharynx or colon cancer not rated as relapse.

The impact of the mammographic image on survival

The significant prognostic impact of the presence of casting-type calcifications on the

mammogram was still observed. Survival data, according to whether the tumour was or was

not associated with casting calcifications, are presented in table 10.

Page 31: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

30

Casting

calcifications

Relapse-

free, n

Surviving

n

Median RFS

months

Median DDFS

months

Median OS

months

Present 1/12 6/12 11.5 11.5 29.6

Absent 28/43 30/43 >100 >100 >100

p 0.01 0.176 <0.001 <0.001 0.035

RFS = Relapse-free survival; DDFS = distant disease-free survival; OS = overall survival.

Table 10 Outcome according to the presence or absence of casting calcifications on the

mammogram

Page 32: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

31

4.4 Cosmetic outcome 1-5 years after breast conservative surgery, irradiation and

systemic therapy

A total of 198 patients were enrolled in the study. The mean age of the population was

62.0±10.6 (range 25-89) years. The median follow-up time was 2.4 (range 1.2-5.9) years.

Most of the tumours measured ≤2.0 cm and were lymph node-negative (Table 11). Data

concerning the radiotherapy are presented in Table 12. One hundred and sixty-seven patients

(84.3%) received only breast irradiation, while 31 patients (15.7%) both breast and regional

lymph node irradiation. Twenty patients (10.1%) were treated with taxane-based

chemotherapy before the radiotherapy. The systemic therapy before the radiotherapy started

with an aromatase inhibitor or tamoxifen alone, in 49 (24.7%) and 48 (24.2%) cases,

respectively. Four (2.0%) and two (1.0%) patients received a taxane-based chemotherapy and

an aromatase inhibitor or tamoxifen thereafter, respectively. Seventy-five patients (37.9%) did

not participate in systemic therapy.

Factors influencing cosmetic outcome

The patients and the physicians considered the cosmetic outcome to be excellent or good in

76.3% and 47% of the cases, respectively; a weak correlation was observed between the

opinions of the physicians and the patients (Table 13).

A large majority of the patients (n=160, 80.8%) underwent their breast surgery at our

institute, and 127 (84.1%) of them regarded the cosmetic outcome as excellent or good more

often than did those who were operated on in smaller surgical departments (n=24/38, 63.2%)

(p=0.05). In the view of the physicians, the cosmetic outcome overall was less often excellent

or good as the tumour size increased: the mean±SD tumour size was 1.3±0.7 and 1.5±0.7 cm

in the excellent and good vs. the fair and poor outcome groups, respectively (p=0.015).

Page 33: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

32

Among those patients who had an ABD, the physician considered the cosmetic outcome

excellent or good in 29 cases (37.7%), and fair or poor in 48 cases (62.3%, p=0.04). A

significant relation or interaction was not detected between these variables in the logistic

regression analysis. The incidence and severity of hyperpigmentation, fibrosis, oedema and

teleangiectasia are presented in Table 14.

Page 34: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

33

Patient and tumour

characteristics

All

n (%)

Systemic therapy

n

Chemotherapy Tamoxifen Aromatase

inhibitor

Chemotherapy and

hormonal therapy

None

Menostatus

Premenopausal 48 (24.2) 12 22 0 4 10

Postmenopausal 150 (75.8) 8 26 49 2 65

Age

≤50 years 20 (10.1) 9 6 0 1 4

>50 years 178 (89.9) 11 42 49 5 71

Lymph node surgery*

Sentinel node biopsy

only

111 (56.0) 6 28 29 3 45

Axillary block

dissection

77 (38.9) 14 18 18 3 24

Tumour size

≤2.0 cm 164 (82.8) 12 41 41 3 67

>2.0 cm 34 (17.2) 8 8 7 3 8

Page 35: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

34

Lymph node positivity

Lymph node-negative 155 (78.3) 8 38 38 1 70

Lymph node-positive 43 (21.7) 12 10 11 5 5

Tumour location

Upper quadrants 130 (65.6) 16 31 33 3 47

Central 34 (17.2) 1 7 11 1 14

Lower quadrants 34 (17.2) 3 10 5 2 14

Smoking habits

Never smoked 125 (63.1) 12 23 38 3 49

Current or previous

smoker

73 (36.9) 8 25 11 3 26

* Ten patients did not participate in lymph node surgery because of their advanced age

Table 11 Patient and tumour characteristics in the overall study population and according to the systemic therapy

Page 36: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

35

Radiotherapy-

related data

All

mean±SD

(range)

Systemic therapy

mean±SD (range)

Chemotherapy Tamoxifen Aromatase

inhibitor

Chemotherapy

and hormonal

therapy

None

Volume of the

irradiated

breast (cm3)

1113.8±479.8

(218-3620)

1093.9±479.8

(404-2059)

974.7 ±447.9

(218-2217)

1140.5±413.5

(484-2358)

882.3 ±292.8

(547-1249)

1209.3±531.9

(425-3620)

V95%–107%

(%)

88.9±2.6

(81-95)

89.3±2.9

(84-95)

88.9±2.7

(81-94)

88.7±2.5

(82-94)

90.0±2.8

(86-94)

89.0± 2.4

(81-94)

V>107%

(%)

0.6±1.1

(0-6.9)

0.4±0.5

(0-1.9)

0.9±1.6

(0-6.9)

0.8±1.2

(0-4.5)

0.1±0.2

(0-0.5)

0.4±0.7

(0-4.1)

Boost volume

(cm3)

79.4±45.3

(13-258)

82.3±39.7 (32-

183)

73.7±43.2

(22-212)

72.6±37.7

(22-199)

69.2±36.5

(32-118)

88.4±53.6

(32-183)

Breast

separation

(cm)

21.7±2.7

(15.1-30.2)

21.6±2.6 (17.9-

25.7)

22.0±2.8

(16.8-30.2)

21.1±3.1

(15.1-30.1)

20.4±1.7

(18.1-22.5)

21.9±2.5

(16.4-28.9)

n (%) n

Boost 161 (81.3)

Page 37: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

36

Photon boost 63 (39.1) 9 14 16 2 22

Electron

boost 98 (60.9) 11 25 26 3 33

10 Gy boost

dose 145 (90.1) 19 35 37 4 50

16 Gy boost

dose 16 (9.9) 1 4 5 1 5

Table 12 Radiotherapy-related data on the overall study population and according to the systemic therapy

Page 38: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

37

Cosmetic outcome Excellent Good Fair Poor

Patient’s opinion (%) 93 (47.0) 58 (29.3) 44 (22.2) 3 (1.5)

Physician’s opinion (%) 32 (16.2) 61 (30.8) 68 (34.3) 37 (18.7)

Kappa 0.09 p<0.05

Table 13 Overall cosmetic outcome in the study population as assessed by the patient and the

physician. The patients’ subjective appreciation and the cosmetic result as classified by the

physician (the absence of any abnormality, or the slight, moderate or severe manifestation of

breast asymmetry or changes of the skin or the breast contour) are indicated.

Page 39: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

38

Score 0 (%) Score 1 (%) Score 2 (%) Score 3 (%)

Hyperpigmentation 127 (64.1) 56 (28.3) 11 (5.6) 4 (2.0)

Fibrosis 131 (66.1) 37 (18.7) 30 (15.2) 0 (0.0)

Oedema 175 (88.4) 14 (7.1) 8 (4.0) 1 (0.5)

Teleangiectasia 176 (88.9) 3 (1.5) 6 (3) 13 (6.6)

Table 14 Incidence and severity of radiogenic changes of the skin, subcutaneous tissue and

breast parenchyma according to the modified scoring system of Johansen et al. [36, 41]

Page 40: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

39

The effect of patient and tumour characteristics on cosmetic outcome

Thirty-one patients (19.7%) complained of pain in the operated breast, while 81 (40.9%)

reported tenderness. Breast tenderness occurred significantly more often among

premenopausal women or patients ≤50 years old (both p<0.05). The average±SD age of the

patients who complained or had no complaint of breast tenderness was 59.8±11.6 and

63.6±9.6 years, respectively (p<0.05). Breast fibrosis and/or oedema occurred in 67 (33.9%)

and 23 (11.6%) patients, respectively. Skin hyperpigmentation, found in altogether 71 patients

(35.9%) occurred in 59 (83.1%) of the patients >50 years old, and 12 (16.9%) of the women

≤50 years old, respectively (p<0.05), and its incidence decreased with the median time

elapsed after radiotherapy (2.1 and 2.5 years in the presence and the absence of

hyperpigmentation, respectively, p=0.02). Teleangiectasia developed in 22 patients (11.1%).

The mean±SD tumour size was 1.6±0.7 cm if moderate dyspigmentation occurred, and

1.3±0.7 cm in the other cases (p<0.05). The average±SD tumour size was 1.9±1.4 cm if breast

marked oedema occurred, and 1.4±0.7 cm in the other cases (p<0.05). Breast oedema

occurred in 15 (65.2%) and 8 (34.8%) among those patients who had or did not have ABD,

respectively (p=0.01). Breast oedema was related to dyspigmentation (p=0.003), fibrosis

(p<0.001) and breast asymmetry (p=0.032), whereas none of these abnormalities were

associated with teleangiectasia.

Changes in body image and clothing habits

Thirty-three (16.7%) patients mentioned changes in their clothing habits and 44 (22.3%) had

experienced a variation in their body image. Those patients who noticed body image changes

were younger than those who did not (the mean±SD age was 57.6±10.1 vs. 63.3±10.4 years,

respectively, p<0.005). Eighty-six percent of the postmenopausal, and 74% of the ≤50 years

old women needed to change their clothing habits (p<0.05), while this measure was 8.9% and

1.3% according to whether the patient received or did not receive systemic therapy,

respectively (p<0.005).

Page 41: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

40

The length of the excisional scar and breast asymmetry

In most cases, the excisional scar was in the upper quadrants (n=130, 65.7%). The mean±SD

length of the scar was 8.2±3.5 (range, 3.0-28.0) cm. An average±SD breast asymmetry

(n=159) of 2.7±1.9 (range, 1.0-15.0) cm was found in 159 of the 194 evaluable patients

(nipple excision was performed in 4 patients). The average±SD extent of breast asymmetry

was 2.4±2.2 cm vs. 1.5±0.9 cm when the tumour was located in the upper vs. the lower

quadrants, respectively (p=0.05), and 2.1±1.7 cm vs. 2.9±2.9 cm when the tumour diameter

was ≤2 cm vs. >2 cm, respectively (p<0.05). The length of the scar did not influence any

attribute of the cosmetic outcome.

Radiotherapy and its effects on the cosmetic outcome

More severe dyspigmentation and breast oedema occurred in patients with larger PTVs

(p<0.001). The risk of more severe dyspigmentation and breast oedema increased by 18% and

23%, respectively, for every 100 cm3 increase in irradiated breast volume (OR=1.18, 95% CI:

1.07-1.31; OR=1.23, 95% CI: 1.12-1.36). Breast oedema was more frequent with increasing

BS (p<0.005), and was not related to nodal irradiation. The incidence of breast fibrosis was

significantly higher with larger PTVs (mean±SD value of PTV, patients with breast fibrosis:

1221.5±571.8 cm3 and patients without fibrosis: 1058.7±416.9 cm

3, p<0.05). The risk of

breast fibrosis increased by 7% for every 100 cm3 increase in irradiated breast volume

(OR=1.07, 95% CI: 1.00-1.14). No association was found between any of the attributes of

cosmesis and the dose inhomogeneity within the irradiated volume. The dose inhomogeneity

was related to the volume of the irradiated breast (p=0.037). The risk of V>107%≥1%

increased by 8% for every 100 cm3 increase in irradiated breast volume (OR=1.078, 95% CI:

1.003-1.158).

A higher boost volume favoured breast fibrosis and oedema (p<0.005 and p<0.001,

respectively). The risk of breast oedema and breast fibrosis increased by 21% and 12%,

respectively, for every 10 cm3 increase in boost volume (OR=1.21, 95% CI: 1.09-1.33 and

OR=1.12, 95%, CI: 1.03-1.12). Breast oedema and/or fibrosis was more frequent among those

patients who received a photon boost than those who received electrons (breast oedema: 13/63

Page 42: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

41

vs. 4/98, p=0.001 and breast fibrosis: 26/63 vs. 26/98, p=0.038). No association was found

between the administration of systemic therapy and cosmetic or functional outcome.

Smoking habits and their effect on cosmetic outcome

One hundred and twenty-five (63.1%) patients had never smoked, 49 (24.7%) had smoked

previously and 24 patients (12.1%) smoked during the radiotherapy. Skin dyspigmentation

and teleangiectasia developed significantly less often among the patients who had never

smoked (both p<0.05).

5. Discussion

Mode of detection, mammographic appearance and multifocality as potential new prognostic

factors in early breast cancer

Our findings in both the smaller and the second, extended database, are in accordance with

those studies which demonstrated that the prognostic factors are more favourable in screen-

detected than in interval or symptomatic cancers. In numerous studies tumours were

obviously smaller, more probably lymph node-negative, [42-48] and better differentiated [44,

46-47] if screen-detected. Some groups have reported that cancers of a special histological

type, such as lobular or tubular carcinomas, are relatively more prevalent among screen-

detected tumours. [44, 46] In contrast, consistent with our data, no difference in histological

type was observed among the different groups in the study by Gill et al. [47] LVI was less

frequently present in screen-detected than in symptomatic cancers in that study. [47] We also

found that LVI was more prevalent in interval or symptomatic cancers than in screen-

detected cancers. It has been suggested previously that one indicator of the less aggressive

biological behaviour of screen-detected cancers is their higher hormone receptor content and

the less frequent expression of HER2. Whereas Gill et al. [47] and Klemi et al. [43] reported

that more screen-detected than symptomatic cancers were ER-positive, Joensuu et al. [46]

did not discern any difference in the expression of ER or HER2 between screen-detected and

symptomatic cancers. Similarly, we did not observe any difference in the ER, PR or HER2

status of the tumours as a function of the mode of detection.

Page 43: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

42

Among screen-detected cancers, less radical surgical interventions were needed, and less

frequent chemotherapy was utilized, as a consequence of the earlier stage of these cancers.

However, the hormone therapy requirements did not differ between the groups as concerns

the mode of detection. This is a consequence of the similar distributions of the hormone

receptor-positive tumours in the different groups, and the frequent use of endocrine therapy

even in the early tumours, with the aim of the prevention of distant metastases, local relapses

or metachronous second breast cancers.

Interval cancers are detected from the symptoms in the interval between scheduled screening

episodes. A failure to detect breast cancer during screening depends on the testing procedure,

the interpretation by the radiologist, and the patient and tumour characteristics. A

biennial screening interval, a younger age [49-52] and increased breast density [52] favour

detection failure. More importantly, the nature of interval cancers may influence their

detection. Interval cancers have been demonstrated to occur more often in younger women,

and to exhibit a higher proliferation rate, a lower ER expression and higher HER2 expression

[49-52]. In our series, the interval cancers were significantly different from the screen-

detected cancers, and similar to the symptomatic cancers, as regards the tumour size, the

lymph node status, the presence of LVI and the grade, but the differences in histological type,

and ER/PR or HER2 status did not reach the level of statistical significance. This latter

inconsistency with the literature data may be explained by the relatively low number of cases

in our study. We found that a significant proportion of the interval cancers were

mammographically occult even at the time of diagnosis. These tumours belong among a

special subtype of interval cancers known as occult cancers [53].

Besides the classical prognostic factors (pT, lymph node status, grade, the presence or

absence of LVI, and the expressions of the hormone receptors and HER2), however, other

specific indicators for a better identification of the high-risk cases are needed. The

mammographic appearance of the cancer has recently been suggested as a prognostic factor

[2, 1-16, 54]. The risk of relapse or mortality in high-risk breast cancer patients was earlier

found to be about threefold if the tumour was associated with casting calcifications on the

mammogram [16]. In contrast, a highly favourable prognosis was experienced in small breast

cancers appearing as stellate lesions on the mammogram [2, 14]. We also analyzed the

potential role of mammographic image as a prognostic factor in a large database with a

Page 44: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

43

relatively large proportion of very good prognosis and short follow-up time, and also in 55

high-risk breast cancer patients with a longer follow-up. The outcome of this latter analysis is

consistent with the literature data, and points to the long-persisting extreme difference in

prognosis between cases with or without casting calcifications on the mammogram. Our

observations underline that casting-type calcifications are not merely a marker of early

relapse, but a marker of a special biologic nature with very poor outcome.

The prognostic significance of multifocality and the tumour burden have been investigated by

many authors, but the results are inconclusive due to the different nomenclature used [1, 18-

23]. In general, multifocality is defined as the presence of two or more tumour foci separated

by normal breast parenchyma. Some studies have attempted to analyze the association

between the entire tumour burden and the outcome, by using the aggregate measure of the

dimensions or volumes of the tumour foci [20, 22, 58, 59]. These factors have been

demonstrated as determinants of poorer characteristics and outcome [1, 18, 19, 21-24]. This is

why we intended to study these tumour features for the characterisation of breast carcinomas.

In our extended database of operated early breast cancer patients, we found, that although

multifocal breast tumours (frequently screen-detected) are often smaller than unifocal breast

tumours, the aggregate size and hence the load of the cancer are larger, indicating a higher

risk of dissemination. The relatively high proportion of lymph node-positive cases in invasive

multifocal cancers reflects their aggressive behaviour and advanced stage. Although our

results do not support the role of multifocality as an independent predictor of a worse

prognosis, they should warn against the consideration of only a single tumour focus rather

than the whole extent of the disease if multiple cancer foci are present so as to avoid false

judgement.

In our study, multifocality and “invasive multifocality” occurred within the ranges reported by

other authors [22, 24, 55]. There are a number of reasons for the discrepancies between the

findings. Some authors do not distinguish between multicentric (situated in different

quadrants of the breast) and multifocal cancers [18], and include tumours with a single

invasive focus and in situ components [24], whereas others regard tumours as multifocal only

if more than one invasive focus is present [1, 19-22, 24, 56]. The strength of our study is that

we relied on data recorded in thorough examinations of large-format histopathology slides.

Nonetheless the retrospective nature of the study is a disadvantage.

Page 45: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

44

The UICC/AJC TNM system is used as a prognostic tool, and the TNM stage has long served

as the basis of therapy decision-making. A major flaw is that, in cases of multifocality, the T

stage indicates the largest invasive focus of the disease, but ignores the effective tumour

burden, which may be significant if multiple foci are present. Our study accords with the

findings of others in that the TNM system in its current form is not suitable for these purposes

in the population of multifocal breast cancers [18, 21, 56, 58]. We found that, despite the

tumour being smaller, lymph node positivity was more prevalent among cancers containing

multiple invasive foci, and a larger aggregate tumour burden involved a poorer outcome.

These results are in accordance with those [18, 20, 22, 24, 58, 59] indicating that multifocality

is related to lymph node positivity. Moreover, Tot et al. found multifocal and diffuse lesion

distribution to be an independent predictor of breast cancer-related fatality [24]. In fact, the

diffuse distribution of the lesions is a rarely described phenomenon, and consequently its

effect should rather be analysed prospectively [57]. We could not recover this type of tumour

from the pathology records; such cases were probably classified as unifocal, which could play

a role in the incongruence between the findings of Tot et al. and ourselves [24].

For the estimation of tumour extent, we calculated the tumour burden by summing the largest

diameters of the tumour foci. This method provides merely an approximation; only exact

measurement of the entire tumour extent, encompassing the whole of the affected part of the

breast parenchyma, would furnish accurate information. For the estimation of tumour burden,

different approaches have been utilized in the literature. For assessment of the tumour burden

of multifocal cancers and the effect on survival, Rezo et al. used aggregate sizes and volumes

of the tumour foci, calculated as though they were spherical [22]. Interestingly, all measures

gave similar results: increasing tumour size predicted a poorer outcome after 60 months of

follow-up. Others followed the same method as we did, using the combined diameters of the

tumour foci [20, 56, 58].

The effect of multifocality on prognosis is controversial. Similarly to our findings, Cabioglu

et al. concluded that the presence of multiple invasive foci favoured lymph node positivity,

but the 55 month-survival did not differ between multifocal and unifocal cases [20].

Yersuhalmi et al. analysed a dataset on more than 25000 cases, and found that multifocality

carried a 17% extra risk of breast cancer-related death in stage I-III breast cancers [21]. In a

matched-pair analysis of 288 breast cancer cases, Weissenbacher et al likewise showed that

both the risk of relapse and that of death due to breast cancer were increased in multifocal

Page 46: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

45

cancers [18]. Boyages et al. demonstrated a better 10-year survival rate among unifocal breast

cancer cases than among multifocal breast cancer cases, but this effect was restricted to

tumours >20 mm [56]. In a series of 574 breast cancer cases, Tot et al. observed a

significantly poorer BCSS rate in multifocal cancers, irrespective of whether only invasive or

invasive plus in situ multifocal cases were included [24]. We did not detect a difference in

survival between the cases with multifocal and unifocal breast cancers, but tumour size,

lymph node status and HER2-positive or triple negative status were independent predictors of

outcome. The relatively low overall number of events and short follow-up times could have

played a role in these results.

In Hungary, the national mammographic breast-screening program was introduced in 2001.

The quality indicators of the screening closely match the European guidelines, with the

exception of the participation rate, which is around 40%. However, the proportion of women

regularly screened for breast cancer is more than 60% as a result of the contribution of

opportunistic screening. Thus, in this mixed population of early breast cancer patients, the use

of tumour features such as the mode of detection and the mammographic appearance, the

multifocality of the tumour represent useful tools for individualized care.

Evaluation of the cosmetic and functional outcomes after breast-conserving surgery and

conformal radiotherapy, with or without adjuvant systemic therapy

The cosmetic and the functional outcome after the surgical and oncoradiological treatment

play an important role in the breast cancer patients’ quality of life. These factors depend on

many patient- and therapy-related characteristics. The age, the menopausal status, the weight

and the general health status of the patient, the stage of the tumour and the surgical

intervention clearly influence the results [30]. The radiogenic changes of the breast depend on

the irradiation’s features and the individual radiosensitivity [30-33]. Adjuvant chemotherapy

[41] and tamoxifen therapy [41, 76] have been suggested to predict a poor cosmetic outcome

[38].

More than three-quarters of the patients considered the cosmetic outcome to be excellent or

good, which is similar to the observations by other groups [36, 38, 60]. In contrast, in the

opinion of the physicians, only about half of the cases belonged in this category. One

explanation of the discrepancy might be the strict conditions used for the evaluation of the

Page 47: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

46

cosmetic appearance. A further contributing factor could have been the relatively short

follow-up time in our study since the consideration of the radiation side-effects by the patient

may change in time [37].

The location and stage of the tumour clearly determine the cosmetic outcome [36, 60-64]. In

our study, breast oedema, fibrosis, teleangiectasia and dyspigmentation were all related to the

size of the tumour, and were interrelated. Similarly as in the studies by Johansen et al. and

Taylor et al., we found that tumours located in the upper quadrants and those with a larger

diameter were predisposed to more severe breast asymmetry [36, 60].

The available data are not completely unequivocal as regards the relation between a young

age and the cosmetic and functional outcomes. Most studies report an improved cosmetic

outcome among younger women [38, 60, 65, 66] though the opposite to has been suggested

[36]. We did not find any age-specific differences in the overall cosmetic outcome. However,

the different components of the cosmetic and functional results did depend on the age of the

patient. The more frequent breast tenderness or pain among ≤50 years old women might have

been related to hormonal effects and the change in body image in this age group could have

been dependent on psychological or mental factors. The higher incidence of dyspigmentation

in those over 50 years of age is probably due to the age-dependent response to radiation, with

an increased accumulation of melanin and lipofuscin, the pigments related to aging and

oxidative stress [67]. It is well known that radiogenic side-effects are more frequent for larger

breasts. Nevertheless, to the best of our knowledge, this analysis is the first to report cosmetic

results after conformal breast radiotherapy in relation to dose-volume data. Although

conformal radiotherapy was applied in the study by Lilla et al., a detailed analysis of the

radiotherapy-related data was not reported [66]. In that and other studies, the associations

between the side-effects and the irradiated volume were based on approximate data such as

the size of the breast or the bra cup [36, 41, 66, 68, 69] and the chest wall separation [68].

Likewise, dose homogeneity in the entire PTV was predicted after visualization of the dose

distribution at the central axis [64, 68] or was related to the use or avoidance of tissue

compensators or wedges [60, 70, 71]. In one of these studies, the dose homogeneity

demonstrated a parallel with the breast size [68], an effect confirmed by our results. In our

study, no association was detected between the dose inhomogeneity and poorer cosmesis as a

result of restricting the overdosed volume (V>107%) to 1% of the PTV, and the superposition

Page 48: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

47

of individually weighted 6 or 15 MV segmental fields to the tangential fields [40]. Our

finding that the photon boost was more often related to breast oedema and fibrosis is in

accordance with the outcome of the robust analysis by Murphy et al. [69]. We consider that

this phenomenon is a consequence of the larger volume irradiated when 2 photon fields are

applied as compared with the use of one direct electron field. For the best cosmetic result, the

use of an electron boost is recommended, or the intensity-modulated radiation therapy

(IMRT) technique may be utilized [72-74].

Systemic therapy has been found detrimental to the cosmetic and functional outcome in many

studies [35, 41, 60, 64, 69, 75]. Most investigated the effects of chemotherapy with

cyclophosphamide, methotrexate and fluorouracil (CMF) or an antracycline-containing

regimen, either concurrently or sequentially with radiotherapy [36, 60, 75]. In the study by

Johansen et al., chemotherapy with CMF or with tamoxifen was associated with a 5-fold

(CMF) or 10-fold (tamoxifen) higher risk of breast fibrosis, respectively [36]. Taxane-based

combinations have become a routine option in adjuvant chemotherapy, but the effects of

sequentially applied taxane-based chemotherapy on breast cosmesis have not yet been

reported. We did not detect adverse effects of such a regimen, though the number of patients

was low. The third-generation aromatase inhibitors currently compromise the standard

endocrine therapy of postmenopausal women with hormone-dependent breast cancer.

However, tamoxifen is still administered in premenopausal and selected postmenopausal

women. Azria et al. demonstrated in their primal work that letrozole does not exert a

detrimental effect on early or late radiation skin toxicity [33]. In accordance with these

findings, aromatase inhibitor therapy in our analysis did not have any effect on the studied

parameters. In contrast, the prospective study by Azria et al. revealed that the concurrent

administration of tamoxifen with radiotherapy doubled the risk of subcutaneous fibrosis [31].

Likewise, we found that concomitant tamoxifen increased the risk of lung fibrosis

(OR=2.442) [40]. Due to the limitations of the analyses, other reports have not provided a

clear answer as to the effect of simultaneous tamoxifen therapy with radiotherapy on the

cosmetic outcome [41, 60, 61, 76]. Our survey suggested that tamoxifen therapy was related

to the change in body image, but since no specific radiogenic changes were detected, the

frequent weight gain associated with this medication may have played a role in this outcome

measure.

Page 49: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

48

The patient and tumour characteristics influence significantly the cosmetic outcome; therapy-

related factors can also modify the breast aesthetics and the patient well-being. Although most

of the patients were satisfied with the cosmetic outcome, individual planning of the

oncoradiological therapy has considerable importance of reaching the best cosmetic result.

6. Summary, conclusions

6.1 Our findings reveal that screen-detected cancers have a more favourable

prognosis and need less oncological treatment than do tumours detected outside

mammographic service screening. The mammographic appearance of a tumour reflects its

biological behaviour, and should be considered when the management is to be optimized.

6.2 For the adequate management of breast cancer, an appropriate assessment of the

tumour distribution is essential; heightened attention is needed during the care of multifocal

breast cancers, which present in a more advanced stage than estimated from a he

consideration of only the largest focus.

6.3 Our results gave further evidence of the poorer prognosis of those tumours which show

casting-type calcification on the mammogram and highlight the importance of this special

type of tumour features.

6.4 The cosmetic outcome after breast-conserving surgery is primarily determined by the

stage of the disease and the consequences of radiotherapy. Despite the achievements made

regarding the effectiveness and side-effect profile of modern radiotherapy, a careful estimate

of its benefits remain necessary in each case and determination of the individual treatment

strategy accordingly.

Page 50: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

49

7. Acknowledgements

I wish to express my special thanks to my supervisor Professor Zsuzsanna Kahán director of

the Department of Oncotherapy, University of Szeged for her support and scientific guidance

of my work.

I would like to thank Professor László Thurzó former director of the Department of

Oncotherapy, University of Szeged, who provided excellent working conditions for me at the

institute.

Special thanks are due to the staff members of the breast board: Professor György Lázár,

Attila Paszt, Zsolt Simonka, Katalin Ormándi, Csilla Hoffmann, Sándor Hamar, László

Kaizer, András Vörös, Erika Csörgő, Máté Lázár, without whom this task would never have

been fulfilled.

Special thanks are also due to Tibor Nyári, József Eller and Zoltán Varga for their guidance in

the statistical analysis.

I greatly appreciate all the support and work of high standard provided by physicians,

technicians and physicists of the Department of Oncotherapy, University of Szeged that

helped this dissertation to be born.

I would like to thank to my family and friends for encouraging and supporting me.

Page 51: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

50

8. References

1. Tot T. The metastatic capacity of multifocal breast carcinomas: extensive tumours

versus tumours of limited extent. Hum Pathol 2009; 40: 199-205.

2. Tabar L, Chen THH, Yen AMF, Tot T, Tung TH et al. Mammographic tumour

features can predict long-term outcomes reliably in women with 1-14-mm invasive breast

carcinoma. Cancer 2004; 101: 1745-1759.

3. Tot T, Kahán Z. Springer, Dordrecht, Heidelberg, London, New York, 2011. pp. 1-22.

A new approach to early breast cancer. In: Breast cancer, a heterogeneous disease entity.

The very early stages.

4. Kahán Z. New approaches for the classification of early breast cancer, a heterogeneous

disease entity. memo, 2011; 4: 135-139.

5. Majek O, Danes J, Skovajsova M, Bartonkova H, Buresova L et al. Breast cancer

screening in the Czech Republic: time trends in performance indicators during the first seven

years of the organised programme. BMC Public Health 2011; 11: 288.

6. Gill PG, Farshid G, Luke CG, Roder DM. Detection by screening mammography is a

powerful independent predictor of survival in women diagnosed with breast cancer. Breast

2004; 13: 15-22.

7. Tabar L, Fagerberg G, Duffy SW et al. The Swedish two-county trial of

mammographic screening for breast cancer: recent results and calculation of benefit. J

Epidemiol Community Health 1989; 43:107–114

8. Tabar L, Yeng M-F, Vitak B et al. Mammography service screening and mortality in

breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet

2003; 361:1405–1410

9. The Swedish Organised Service Screening Evaluation Group Reduction of breast

cancer mortality from organised service screening with mammography: 1. Further

confirmation with extended data. Cancer Epidemiol Biomarkers Prev 2006; 15:45–51

10. Miller AB, Baines C, To T et al. Canadian national breast screening study. 1. Breast

cancer detection and death rates among women aged 40 to 49 years. 1992; CMAJ 147:1459–

1476

Page 52: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

51

11. Kerlikowske K, Grady D, Rubin SM et al. Efficacy of screening mammography. A

meta-analysis. JAMA 1995; 273:149–154

12. Tabar L, Dean PB, Kaufman CS et al. A new era in the diagnosis of breast cancer.

Surg Oncol Clinics NA 2000; 9:233–277

13. Thurfjell E, Thurfjell MG, Lindgren A Mammographic finding as predictor of

survival in 1–9 mm invasive breast cancers. Worse prognosis for cases presenting as

calcifications alone. Breast Cancer Res Treat 2001; 67:177–180

14. Alexander MC, Yankaskas BC, Biesemier KW Association of stellate mammographic

pattern with survival in small invasive breast tumours. Am J Roentgenol 2006; 187:29–73

15. Peacock C, Given-Wilson RM, Duffy SW Mammographic casting-type calcification

associated with small screen-detected invasive breast cancers: is this a reliable prognostic

indicator? Clin Radiol 2004; 59:165–170

16. Pálka I, Ormándi K, Gaál S et al. Casting-type calcifications on the mammogram

indicate a higher probability of early relapse and death among operable high-risk breast

cancer patients. Acta Oncol 2007; 46(8):1178-83.

17. Alexander MC, Yankaskas BC, Biesemier KW Association of stellate mammographic

pattern with survival in small invasive breast tumours. Am J Roentgenol 2006; 187:29–73

18. Weissenbacher TM, Zschage M, Janni W, Jeschke U, Dimpfl T et al. Multicentric and

multifocal versus unifocal breast cancer: is the tumour-node-metastasis classification

justified? Breast Cancer Res Treat 2010; 122: 27-34.

19. Tot T, Pekar G, Hofmeyer S, Sollie T, Gere M, Tarjan M. The distribution of lesions

in 1-14-mm invasive breast carcinomas and its relation to metastatic potential. Virchows

Arch 2009; 455: 109-115.

20. Cabioglu N, Ozmen V, Kaya H, Tuzlali S, Igci A et al. Increased lymph node

positivity in multifocal and multicentric breast cancer. J Am Coll Surg 2009; 208: 67-74.

21. Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C et al. Does

multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of

survival and contralateral breast cancer incidence. Breast Cancer Res Treat 2009; 117: 365-

370.

22. Rezo A, Dahlstrom J, Shadbolt B, Rodins K, Zhang Y et al. Tumour size and survival

in multicentric and multifocal breast cancer. Breast 2011; 20: 259-263.

Page 53: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

52

23. Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y et al. Breast-conserving

therapy for macroscopically multiple cancers. Ann Surg 1990; 212: 38-44.

24. Tot T, Gere M, Pekar G, Tarjeb M, Hofmeyer S et al. Breast cancer multifocality,

disease extent, and survival. Hum Pathol 2011; 42: 1761-9

25. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al.

Differences in risk factors for local and distant recurrence after breast-conserving therapy or

mastectomy for stage I and II breast cancer: pooled results of two large European

randomized trials. J Clin Oncol 2001; 19:1688-1697.

26. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-

year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and

lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;

347:1233-1241.

27. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-

year follow-up of a randomized study comparing breast-conserving surgery with radical

mastectomy for early breast cancer. N Engl J Med 2002; 347:1227-1232.

28. Offersen BV, Overgaard M, Kroman N, Overgaard J. Accelerated partial breast

irradiation as part of breast conserving therapy of early breast carcinoma: a systematic

review. Radiother Oncol 2009; 90:1-13.

29. Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, et al.

Tamoxifen with or without breast irradiation in women 50 years of age or older with early

breast cancer. N Engl J Med 2004; 351:963-970.

30. Munshi A, Kakkar S, Bhutani R, Jalali R, Budrukkar A, Dinshaw KA. Factors

influencing cosmetic outcome in breast conservation. Clin Oncol (R Coll Radiol) 2009;

21:285-293.

31. Azria D, Gourgou S, Sozzi WJ, Zouhair A, Mirimanoff RO, Kramar A, et al.

Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in

hypersensitive patients. Br J Cancer 2004; 91:1251-1260.

32. Azria D, Betz M, Bourgier C, Sozzi WJ, Ozsahin M. Identifying patients at risk for

late radiation-induced toxicity. Crit Rev Oncol Hematol, 2010; Epub ahead of print.

33. Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, et al.

Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for

Page 54: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

53

early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol 2010;

11:258-265.

34. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet

A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving

therapy of early breast cancer: 10-year results of the randomized boost versus no boost

EORTC 22881-10882 trial. J Clin Oncol 2007; 25:3259-3265.

35. Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, et al.

Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast

cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. Eur J

Cancer 2008; 44:2587-2599.

36. Johansen J, Overgaard J, Rose C, Engelholm SA, Gadeberg CC, Kjaer M, et al.

Cosmetic outcome and breast morbidity in breast-conserving treatment--results from the

Danish DBCG-82TM national randomized trial in breast cancer. Acta Oncol 2002; 41:369-

380.

37. Curran D, van Dongen JP, Aaronson NK, Kiebert G, Fentiman IS, Mignolet F, et al.

Quality of life of early-stage breast cancer patients treated with radical mastectomy or

breast-conserving procedures: results of EORTC Trial 10801. The European Organization

for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group

(BCCG). Eur J Cancer 1998; 34:307-314.

38. Cardoso MJ, Cardoso J, Santos AC, Vrieling C, Christie D, Liljegren G, et al. Factors

determining esthetic outcome after breast cancer conservative treatment. Breast J 2007;

13:140-146.

39. Nikolenyi A, Sukosd F, Kaizer L, Csorgo E, Voros A et al. Tumour topoisomerase II

alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast

cancer. Oncology 2011; 80: 269-277

40. Kahan Z, Csenki M, Varga Z, Szil E, Cserhati A, Balogh A, et al. The risk of early and

late lung sequelae after conformal radiotherapy in breast cancer patients. Int J Radiat Oncol

Biol Phys 2007; 68:673-681.

41. Johansen J, Overgaard J, Overgaard M. Effect of adjuvant systemic treatment on

cosmetic outcome and late normal-tissue reactions after breast conservation. Acta Oncol

2007; 46:525-533.

Page 55: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

54

42. Moody-Ayers SY, Wells CK, Feinstein AR ”Benign” tumours and ”early

detection” in mammography-screened patients of a natural cohort with breast cancer. Arch

Intern Med 2000; 160:1109–1115

43. Klemi PJ, Joensuu H, Tikkanen S et al. Aggressiveness of breast cancers found with

and without screening. Br Med J 1992; 304:467–469

44. Klemi PJ, Parvinen I, Pylkkanen L et al. Significant improvement in breast cancer

survival through population-based mammography screening. Breast 2003; 12:308–313

45. Anttinen J, Kautiainen H, Kuopo T Role of mammography screening as a predictor of

survival in postmenopausal breast cancer patients. Br J Cancer 2006; 94:147–151

46. Joensuu H, Lehtimäki T, Holli K et al. Risk for distant recurrence of breast cancer

detected by mammography screening or other methods. JAMA 2004; 292:1064–1073

47. Gill PG, Farshid G, Luke CG et al. Detection by screening mammography is a

powerful independent predictor of survival in women diagnosed with breast cancer. Breast

2005;13:15–22

48. Ernst MF, Voogd AC, Goebergh JWW et al. Breast carcinoma diagnosis, treatment,

and prognosis before and after the introduction of mass mammographic screening. Cancer

2004; 100:1337–1344

49. Porter PJ, El-Bastawissi AZ, Mandelson MT et al. Breast tumour characteristics as

predictors of mammographic detection: Comparison of interval- and screen-detected

cancers. J Natl Cancer Inst 1999; 91:2020–2028

50. Gilliland FD, Joste N, Stauber PM et al. Biologic characteristics of interval and

screen-detected breast cancers. J Natl Cancer Inst 2000; 92:743–749

51. Crosier M, Scott D, Wilson RG et al. Differences in Ki67 and c-erbB2 expression

between screen-detected and true interval breast cancers. Clin Cancer Res 1999; 5:2682–

2688

52. Porter GJ, Evans AJ, Cornford EJ et al. Influence of mammographic

parenchymal pattern in screen-detected and interval invasive breast cancers on pathologic

features, mammographic features, and patient survival. Am J Roentgenol 2007; 188:676–

683

53. Porter GJ, Evans AJ, Burrell HC et al. NHSBSP type 1 interval cancers: a

scientifically valid grouping? Clin Radiol 2007; 62:262–267

Page 56: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

55

54. Zunzunegui RG, Chung MA, Oruwari J et al. Casting-type calcifications with

invasion and high-grade ductal carcinoma in situ. Arch Surg 2003; 138:537–540

55. Bendifallah S, Werkoff G, Borie-Moutafoff C, Antoine M, Chopier J et al. Multiple

synchronous (multifocal and multicentric) breast cancer: clinical implications. Surg Oncol

2010; 19: 115-23.

56. Boyages J, Jayasinghe UW, Coombs N. Multifocal breast cancer and survival: each

focus does matter particularly for larger tumours. Eur J Cancer 2010; 46: 1990-1996.

57. Tot T. The diffuse type of invasive lobular carcinoma of the breast: morphology and

prognosis. Virchows Arch 2003; 443: 718-724.

58. Andea AA, Bouwman D, Wallis T, Visscher DW. Correlation of tumour volume and

surface area with lymph node status in patients with multifocal/multicentric breast

carcinoma. Cancer 2004; 100: 20-27.

59. Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: does each focus

matter? J Clin Oncol 2005; 23: 7497-7502.

60. Taylor ME, Perez CA, Halverson KJ, Kuske RR, Philpott GW, Garcia DM, et al.

Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat

Oncol Biol Phys 1995; 31:753-764.

61. Wazer DE, Morr J, Erban JK, Schmid CH, Ruthazer R, Schmidt-Ullrich RK. The

effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in

the conservatively treated breast. Cancer 1997; 80:732-740.

62. Van Limbergen E, Rijnders A, van der Schueren E, Lerut T, Christiaens R. Cosmetic

evaluation of breast conserving treatment for mammary cancer. 2. A quantitative analysis of

the influence of radiation dose, fractionation schedules and surgical treatment techniques on

cosmetic results. Radiother Oncol 1989; 16:253-267.

63. Borger JH, Kemperman H, Smitt HS, Hart A, van Dongen J, Lebesque J, et al. Dose

and volume effects on fibrosis after breast conservation therapy. Int J Radiat Oncol Biol

Phys 1994; 30:1073-1081.

64. Wazer DE, DiPetrillo T, Schmidt-Ullrich R, Weld L, Smith TJ, Marchant DJ, et al.

Factors influencing cosmetic outcome and complication risk after conservative surgery and

radiotherapy for early-stage breast carcinoma. J Clin Oncol 1992; 10:356-363.

65. Pezner RD, Patterson MP, Hill LR, Vora NL, Desai KR, Lipsett JA. Breast retraction

assessment. Multiple variable analysis of factors responsible for cosmetic retraction in

Page 57: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

56

patients treated conservatively for stage I or II breast carcinoma. Acta Radiol Oncol 1985;

24:327-330.

66. Lilla C, Ambrosone CB, Kropp S, Helmbold I, Schmezer P, von Fournier D, et al.

Predictive factors for late normal tissue complications following radiotherapy for breast

cancer. Breast Cancer Res Treat 2007; 106:143-150.

67. Porta EA. Pigments in aging: an overview. Ann N Y Acad Sci 2002; 959:57-65.

68. Moody AM, Mayles WP, Bliss JM, A'Hern RP, Owen JR, Regan J, et al. The

influence of breast size on late radiation effects and association with radiotherapy dose

inhomogeneity. Radiother Oncol 1994; 33:106-112.

69. Murphy C, Anderson PR, Li T, Bleicher RJ, Sigurdson ER, Goldstein LJ, et al. Impact

of the radiation boost on outcomes after breast-conserving surgery and radiation. Int J Radiat

Oncol Biol Phys 2011 Sep 1;81(1):69-76.

70. Ellenbogen R, Jankauskas S, Collini FJ. Achieving standardized photographs in

aesthetic surgery. Plast Reconstr Surg 1990; 86:955-961.

71. Sarin R, Dinshaw KA, Shrivastava SK, Sharma V, Deore SM. Therapeutic factors

influencing the cosmetic outcome and late complications in the conservative management of

early breast cancer. Int J Radiat Oncol Biol Phys 1993; 27:285-292.

72. Hill-Kayser CE, Chacko D, Hwang WT, Vapiwala N, Solin LJ. Long-term clinical and

cosmetic outcomes after breast conservation treatment for women with early-stage breast

carcinoma according to the type of breast boost. Int J Radiat Oncol Biol Phys, 2011; Mar

15;79(4):1048-54.

73. Harsolia A, Kestin L, Grills I, Wallace M, Jolly S, Jones C, et al. Intensity-modulated

radiotherapy results in significant decrease in clinical toxicities compared with conventional

wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys 2007; 68:1375-1380.

74. McDonald MW, Godette KD, Whitaker DJ, Davis LW, Johnstone PA. Three-year

outcomes of breast intensity-modulated radiation therapy with simultaneous integrated

boost. Int J Radiat Oncol Biol Phys 2010; 77:523-530.

75. Abner AL, Recht A, Vicini FA, Silver B, Hayes D, Come S, et al. Cosmetic results

after surgery, chemotherapy, and radiation therapy for early breast cancer. Int J Radiat

Oncol Biol Phys 1991; 21:331-338.

Page 58: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

57

76. Fowble B, Fein DA, Hanlon AL, Eisenberg BL, Hoffman JP, Sigurdson ER, et al. The

impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen

receptor-positive early-stage breast cancer. Int J Radiat Oncol Biol Phys 1996; 35:669-677.

Page 59: INDIVIDUALIZED TREATMENT OF EARLY BREAST CANCERdoktori.bibl.u-szeged.hu/1366/1/KELEMEN_GYONGYI_DR_Dolgozat.pdf · Kelemen G, Uhercsak G, Ormandi K, Eller J, Thurzo L, Kahan Z Long-term

58

APPENDIX